DE202021004005U1 - Ofatumumab zur Behandlung von MS unter Beibehaltung des IgG im Serum - Google Patents

Ofatumumab zur Behandlung von MS unter Beibehaltung des IgG im Serum Download PDF

Info

Publication number
DE202021004005U1
DE202021004005U1 DE202021004005.6U DE202021004005U DE202021004005U1 DE 202021004005 U1 DE202021004005 U1 DE 202021004005U1 DE 202021004005 U DE202021004005 U DE 202021004005U DE 202021004005 U1 DE202021004005 U1 DE 202021004005U1
Authority
DE
Germany
Prior art keywords
ofatumumab
treatment
igg
cell
patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE202021004005.6U
Other languages
German (de)
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of DE202021004005U1 publication Critical patent/DE202021004005U1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE202021004005.6U 2020-04-09 2021-04-09 Ofatumumab zur Behandlung von MS unter Beibehaltung des IgG im Serum Active DE202021004005U1 (de)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP20169007.0 2020-04-09
EP20169007 2020-04-09
EP20176057 2020-05-22
EP20176057.6 2020-05-22
US202063076628P 2020-09-10 2020-09-10
US63/076,628 2020-09-10
US202163166054P 2021-03-25 2021-03-25
US63/166,054 2021-03-25

Publications (1)

Publication Number Publication Date
DE202021004005U1 true DE202021004005U1 (de) 2022-05-06

Family

ID=75362645

Family Applications (1)

Application Number Title Priority Date Filing Date
DE202021004005.6U Active DE202021004005U1 (de) 2020-04-09 2021-04-09 Ofatumumab zur Behandlung von MS unter Beibehaltung des IgG im Serum

Country Status (12)

Country Link
US (1) US20230151106A1 (https=)
EP (3) EP4707302A2 (https=)
JP (2) JP7794757B2 (https=)
KR (1) KR20220166827A (https=)
CN (1) CN115427068A (https=)
AU (1) AU2021253674A1 (https=)
BR (1) BR112022019038A2 (https=)
CA (1) CA3176574A1 (https=)
DE (1) DE202021004005U1 (https=)
IL (1) IL296701A (https=)
MX (1) MX2022012600A (https=)
WO (1) WO2021204994A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3733712T (lt) 2016-08-15 2023-09-11 Novartis Ag Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą
US20220389109A1 (en) * 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
WO2022219057A1 (en) * 2021-04-14 2022-10-20 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009407A1 (en) 2007-07-06 2009-01-15 Smithkline Beecham Corporation Antibody formulations

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0315295C1 (pt) 2002-10-17 2021-05-25 Genmab As anticorpo monoclonal humano isolado, célula hospedeira procariótica, composição farmacêutica, molécula biespecífica, usos de um anticorpo, métodos in vitro de detectar a presença de antígeno de cd20 ou uma célula que expressa cd20 em uma amostra, kit, e, vetor de expressão
WO2012018704A1 (en) * 2010-08-02 2012-02-09 Sanofi-Aventis U.S. Llc Use of teriflunomide for treating multiple sclerosis
EP2748198A2 (en) * 2011-09-27 2014-07-02 The United States of America, as represented by The Secretary, Department of Health and Human Services Method of treating multiple sclerosis by intrathecal depletion of b cells and biomarkers to select patients with progressive multiple sclerosis
LT3733712T (lt) * 2016-08-15 2023-09-11 Novartis Ag Išsėtinės sklerozės gydymo schemos ir būdai, panaudojant ofatumumabą
MX2022003010A (es) * 2019-09-11 2022-06-02 Novartis Ag Tratamiento de la emr mediante cambio de terapia.
US20220389109A1 (en) * 2019-09-11 2022-12-08 Novartis Ag Management of conditions other than multiple sclerosis in ofatumumab-treated patients
WO2022219057A1 (en) * 2021-04-14 2022-10-20 Novartis Ag Ofatumumab for treating multiple sclerosis in asian patients
US20240343821A1 (en) * 2021-08-16 2024-10-17 Novartis Ag Ofatumumab for treating pediatric ms

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009009407A1 (en) 2007-07-06 2009-01-15 Smithkline Beecham Corporation Antibody formulations

Also Published As

Publication number Publication date
JP2023521754A (ja) 2023-05-25
EP4682171A2 (en) 2026-01-21
BR112022019038A2 (pt) 2022-11-01
EP4682171A3 (en) 2026-05-06
CA3176574A1 (en) 2021-10-14
US20230151106A1 (en) 2023-05-18
WO2021204994A1 (en) 2021-10-14
EP4132564A1 (en) 2023-02-15
JP7794757B2 (ja) 2026-01-06
MX2022012600A (es) 2023-02-15
EP4707302A2 (en) 2026-03-11
KR20220166827A (ko) 2022-12-19
IL296701A (en) 2022-11-01
JP2026009900A (ja) 2026-01-21
CN115427068A (zh) 2022-12-02
AU2021253674A1 (en) 2022-11-03

Similar Documents

Publication Publication Date Title
DE69228556T2 (de) CDw52-SPEZIFISCHER ANTIKÖRPER ZUR BEHANDLUNG VON MULTIPLER SKLEROSE
DE60035057T2 (de) CD40 Antagonist zur Behandlung von Psoriasis
DE69624116T3 (de) Verfahren zur behandlung von allergischem asthma
DE69229275T2 (de) Herstellung eines arzneimittels zur behandlung von augenentzündung durch blockierung von zelladhäsionsmolekulen
DE69620174T2 (de) Behandlung von t-zellmediierten autoimmunkrankheiten
KR20060026860A (ko) 신경근 장애의 치료를 위한, 코르티코스테로이드와 조합된미오스타틴 (ｇｄｆ８) 저해제의 용도
DE202021004005U1 (de) Ofatumumab zur Behandlung von MS unter Beibehaltung des IgG im Serum
DE69425246T2 (de) Monoklonale antikoerper gegen lfa-1 zur herstellung eines arzneimittels zur vorbeugung der transplantatabstossung von organen
EP3864053B1 (en) Treatment of rms by switching therapy
DE69825473T2 (de) Cd154-blockadetherapie für das syndrom der hemmung der therapeutischen proteine
DE202017007542U1 (de) Behandlungsschemata zur Behandlung von Multipler Sklerose unter Verwendung von Ofatumumab
US20230167189A1 (en) Treatment of Multiple Sclerosis with Anti-CD52 Antibodies
DE19907094C1 (de) Verwendung von blockierenden Anti-TSH-Rezeptor-Antikörpern bei der Therapie von Hyperthyreosen sowie monoklonale Antikörper für eine solche Verwendung
DE69937057T2 (de) Verwendung von basiliximab zur behandlung von rheumatoider arthritis und hauterkrankungen
JP2024517796A (ja) 抗ｂａｆｆｒ抗体を使用するループス腎炎の治療
DE102020129648A1 (de) Pharmazeutische zusammensetzung
TW202300523A (zh) 用於治療MS同時維持血清IgG之奧法木單抗(OFATUMUMAB)
BR122024017958A2 (pt) Usos de ofatumumab para tratamento de esclerose múltipla (em) enquanto mantém a igg sérica
HK40051003B (en) Treatment of rms by switching therapy
HK40051003A (en) Treatment of rms by switching therapy
DE102017003725A1 (de) Anti-VEGF- und anti-C5-Antikörper zur Behandlung der equinen rezidivierenden Uveitis
HK1090310A (en) Use of myostatin (gdf8) inhibitors in conjunction with corticosteroids for treating neuromuscular disorders

Legal Events

Date Code Title Description
R207 Utility model specification
R150 Utility model maintained after payment of first maintenance fee after three years